Maltodextrin, dextrose equivalent 5.0-8.0
Based on 1 Customer Validation
Maltodextrin, dextrose equivalent 5.0-8.0 can be used as an excipient. Pharmaceutical excipients, or pharmaceutical auxiliaries, refer to other chemical substances used in the pharmaceutical process other than pharmaceutical ingredients. Pharmaceutical excipients generally refer to inactive ingredients in pharmaceutical preparations, which can improve the stability, solubility and processability of pharmaceutical preparations. Pharmaceutical excipients also affect the absorption, distribution, metabolism, and elimination (ADME) processes of co-administered drugs.
For research use only. We do not sell to patients.
- CAS No.: 9050-36-6
- Formula: (C6H10O5)n·xH2O
-
Storage:
Store at room temperature, keep dry and cool.
In solvent -80°C, 1 year , -20°C, 6 months
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
-
HY-W250795
Maltodextrin, dextrose equivalent 16.5-19.5Pharmaceutical Excipient -
HY-W250795A
Maltodextrin, dextrose equivalent 13.0-17.0Polysaccharide -
HY-W250111
Carboxymethyl chitosanWater-soluble Derivative Of Chitosan -
HY-Y1365
GelatinsNatural Materials -
HY-B2144A
Chitosan (MW 150000) (≥85% deacetylated)Bacterial Inhibitor -
HY-Y1365D
Bovine Gelatin,suitable for cell cultureBiochemical Assay Reagent -
HY-Y1365L
Porcine skin Gelatin,suitable for cell culture(high gel strength)Biochemical Assay Reagent -
HY-W134423
Agar, microbiology tested, for cell culture (powder)Biochemical Assay Reagents -
HY-B2144B
Chitosan (MW 30000) (≥85% deacetylated)Bacterial Inhibitor -
HY-B2144K
Chitosan (≥85% deacetylated, viscosity>90 mPa.s, MW 15000)Polysaccharid -
HY-119109
LaminaranImmunotherapy Agent -
HY-B2144E
Chitosan (≥90% deacetylated, Low viscosity,<200mPa.s)Biochemical Assay Reagent
Biological Activity
Description
In Vitro
Maltodextrin, dextrose equivalent 5.0-8.0 is a polysaccharide with good biocompatibility and drug encapsulation ability, that encapsulates BSA as a model protein with an efficiency of about 70% and a loading rate of up to 20%. Maltodextrin, dextrose equivalent 5.0-8.0 exhibits non-toxic to cells at a concentrations of 5 mg/mL, and can be used in drug delivery system. The glucose equivalent (DE) value reflects the degree of hydrolysis of maltodextrin. The higher the DE value, the higher the degree of hydrolysis is. Maltodextrin, dextrose equivalent 5.0-8.0 forms stable nanoparticles with particle sizes ranging from 170 nm to 450 nm and a narrow particle size distribution[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Chemical Information
-
CAS No. 9050-36-6
-
Appearance Solid
-
Formula (C6H10O5)n·xH2O
-
Color White to off-white
-
SMILES
OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@H]2[C@@H](COC)O[C@H](O[H])[C@H](O)[C@H]2O)O1.[y].[x]
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Store at room temperature, keep dry and cool
In solvent -80°C 1 year -20°C 6 months
Solvent & Solubility
In Vitro:
DMSO : 100 mg/mL (Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Protocols
-
Protocol for Pharmacokinetic Study
Pharmacokinetic studies quantify how an organism handles a drug over time through absorption, distribution, metabolism, and excretion, and the core experimental readout is the concentration-time profile of parent drug and, when relevant, metabolites in biological matrices such as plasma, whole blood, urine, bile, or tissue. Pharmacokinetic analysis links dose, route, exposure, clearance, half-life, distribution, bioavailability, and systemic exposure to drug efficacy and toxicity hypotheses rather than measuring a signaling pathway directly. The literature links pharmacokinetics to drug-development phenotypes by showing that drug metabolism and pharmacokinetics influence compound progression, exposure-response interpretation, safety margins, dosing strategy, and failure risk during discovery and development. DMPK science contributes to compound optimization by integrating physicochemical properties, in vitro metabolism, transporter behavior, in vivo exposure, and pharmacodynamic contex
Purity & Documentation
-
Data Sheet (274 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Maltodextrin, dextrose equivalent 5.0-8.0 Related Classifications
HY-W250795B Related Classifications
Powered by Bioz